Why Allogene Therapeutics, Inc.’s (ALLO) Stock Is Down 5.04%
As of Tuesday, November 17, Allogene Therapeutics, Inc.’s ALLO share price has dipped by 5.04%, which has investors questioning if this is right time to buy.Tudor Pop
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Tudor Pop
Jenna Brashear
Tudor Pop
Rosalio Madrigal
Rosalio Madrigal
| Share Statistics | ALLO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $217.5 | $203.5 | 30% |
|
| Shares Out (Mil) | 346.1 | 55.2 | 84% |
|
| Institutional Ownership | 92.7% | 93.3% | 62% |
|
| Float (Mil) | 258.3 | 40.4 | 77% |
|
| Beta | 0.78 | 1.05 | 45% |
|
| Avg Daily Volume (000s) | 11,408 | 569 | 97% |
|
| Price Change (52-week) |
(50.5%) | 38.8% | 21% |
|
| Growth | ALLO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | 9.6% | (10.7%) | 55% |
|
| EPS (5yr) | 19.9% | 15.4% | 68 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (24.6%) | (15.7%) | 26% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 7 | 7 | |
| Current EPS | ($0.153) | ($0.572) | ($0.593) | |
| Month Ago EPS | ($0.141) | ($0.581) | ($0.617) | |
| # Rev Up | 2 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.142) | ($0.586) | ($0.702) | |
| Year/Year Chg | 4.8% | (33.9%) | (43.2%) | |
| Financials | ALLO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $5 | $40 | 5% |
|
| Net Income (TTM) (Mil) | ($175) | ($44) | 7% |
|
| EPS (TTM) | ($0.611) | ($1.400) | 25% |
|
| Operating Cash Flow (TTM) (Mil) | ($109) | ($35) | 6% |
|
| Net Cash Flow (TTM) (Mil) | ($9) | $-0 | 33% |
|
| Long-Term Debt (Q1) (Mil) | $68 | $4 | 41% |
|
| Enterprise Value (Q1) (Mil) | $144 | $142 | 25% |
|
| Valuation | ALLO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.55 | 1.96 | 14% |
|
| P/E | na | 16.9 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | ALLO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.6% | na |
|
| Net Margin | na | (50.8%) | na |
|
| ROA | (36.7%) | (47.0%) | 14% |
|
| ROE | (49.3%) | (51.8%) | 15% |
|
| Liabilities to Assets | 23.2% | 29.6% | 15% |
|
| F-Score | 2 | 3 | 7% |
|
Allogene Therapeutics, Inc. did not pass any screens on 11/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors